BioVersys AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.bioversys.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
- Conditions
- Ventilator Associated Pneumonia
- Interventions
- Drug: BV100 plus Polymyxin B
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 39
- Registration Number
- NCT05685615
- Locations
- 🇬🇪
Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia
🇬🇪Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia
🇬🇪First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 35
- Registration Number
- NCT05684705
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100
- Conditions
- Bacterial Infections
- Interventions
- Drug: BV100 (300 mg)
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 16
- Registration Number
- NCT05684718
- Locations
- 🇭🇺
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 16
- Registration Number
- NCT05537090
- Locations
- 🇭🇺
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 33
- Registration Number
- NCT05537142
- Locations
- 🇭🇺
CRU Hungary Kft., Early Phase Unit, Kistarcsa, Hungary
- Prev
- 1
- 2
- Next
News
BioVersys Secures Critical Chinese Patent for BV100, Advancing Treatment for Deadly Antibiotic-Resistant Infections
• BioVersys has been granted key patent protection in China for BV100, a novel intravenous rifabutin formulation targeting deadly Acinetobacter baumannii infections with mortality rates up to 50%. • The patent expansion to China is strategically significant as the country faces particularly high incidence of Acinetobacter infections with resistance rates of 60-80%, affecting over 1 million patients annually. • BioVersys plans to initiate Phase 1 trials in China soon, followed by inclusion in global Phase 3 registration trials in H2 2025, targeting a global peak sales potential of USD 800 million.